10-Q: Avanos Reports Q3 Loss Amid Goodwill Impairment, Restructuring

Avanos Medical, Inc. reported a significant net loss for the nine months ended September 30, 2025, driven by a $77.0 million goodwill impairment and increased restructuring costs, despite modest net sales growth.

Summary

• Net sales for the three months ended September 30, 2025, increased by 4.3% to $177.8 million, compared to $170.4 million in the prior year period.
• Net sales for the nine months ended September 30, 2025, increased by 2.4% to $520.3 million, compared to $508.2 million in the prior year period.
• The company reported a net loss of $1.4 million for the three months ended September 30, 2025, a decline from a net income of $4.3 million in the same period last year.
• For the nine months ended September 30, 2025, the company incurred a net loss of $71.6 million, a significant decrease from a net income of $5.2 million in the prior year period.
• Operating income for the three months ended September 30, 2025, was $0.1 million, down from $12.0 million in the prior year.
• Operating loss for the nine months ended September 30, 2025, was $64.1 million, compared to an operating income of $22.3 million in the prior year, primarily due to a $77.0 million goodwill impairment.
• Basic and diluted loss per share from continuing operations for the nine months ended September 30, 2025, was $1.55, compared to earnings per share of $0.23 in the prior year.
• Specialty Nutrition Systems (SNS) net sales grew by 16.1% in Q3 2025 and 9.4% year-to-date, driven by strong demand in enteral feeding and neonate solutions.
• Pain Management and Recovery (PM&R) net sales increased by 2.1% in Q3 2025 and 1.6% year-to-date, with Radiofrequency Ablation (RFA) solutions growing 10.5% in Q3 and 10.9% year-to-date, partially offset by a decline in surgical pain and recovery products.
• The company acquired Nexus Medical, LLC on September 11, 2025, for $27.0 million cash plus up to $20.0 million in contingent consideration, to enhance its SNS portfolio.
• The company sold substantially all assets of its Hyaluronic Acid (HA) product line on July 31, 2025, aligning with its strategic focus on PM&R and SNS segments.
• Restructuring costs related to the Post-RH Divestiture Plan were $10.3 million in Q3 2025 and $17.9 million year-to-date, with an expectation of up to $10.0 million in incremental expenses and annualized savings of $15.0 million to $20.0 million from expanded initiatives through 2026.
• Cash and cash equivalents decreased by $37.2 million to $70.5 million as of September 30, 2025, from $107.7 million at December 31, 2024, due to capital expenditures, the Nexus acquisition, and debt repayments.
• Long-term debt decreased to $93.4 million as of September 30, 2025, from $125.3 million at December 31, 2024.

Sentiment

Score: 3

Explanation: The company's financial performance for the nine months ended September 30, 2025, was significantly negative, marked by a substantial net loss and operating loss primarily due to a large goodwill impairment. While there was modest revenue growth in key segments and strategic portfolio adjustments (Nexus acquisition, HA divestiture), the ongoing and expanded restructuring efforts, coupled with potential risks like RFA reimbursement changes and tariffs, indicate significant challenges and uncertainty. The overall sentiment is negative due to the poor financial results and ongoing operational complexities.

Positives

• Net sales increased by 4.3% for the three months and 2.4% for the nine months ended September 30, 2025, demonstrating continued revenue growth.
• Specialty Nutrition Systems (SNS) segment showed strong performance with 16.1% net sales growth in Q3 2025 and 9.4% year-to-date, driven by high demand in enteral feeding and neonate solutions.
• Radiofrequency Ablation (RFA) solutions within the Pain Management and Recovery (PM&R) segment achieved significant growth of 10.5% in Q3 2025 and 10.9% year-to-date, reflecting strong momentum in generator sales and procedural volumes.
• The acquisition of Nexus Medical, LLC is expected to enhance the SNS portfolio with proprietary anti-reflux needleless connector technology for high-acuity settings.
• The sale of the Hyaluronic Acid (HA) product line aligns with the company's strategic transformation to focus on core PM&R and SNS segments.
• Cash provided by operating activities increased to $46.5 million for the nine months ended September 30, 2025, from $42.8 million in the prior year.
• Long-term debt was reduced to $93.4 million as of September 30, 2025, from $125.3 million at December 31, 2024, indicating improved debt management.
• The expanded Post-RH Divestiture Plan is anticipated to generate annualized savings of $15.0 million to $20.0 million.

Negatives

• The company reported a net loss of $1.4 million for Q3 2025 and a substantial net loss of $71.6 million for the nine months ended September 30, 2025, a significant deterioration from prior year's net income.
• Operating income declined sharply to $0.1 million in Q3 2025 and resulted in an operating loss of $64.1 million for the nine months, primarily due to a $77.0 million goodwill impairment.
• Gross profit decreased by 7.4% in Q3 2025 and 5.4% year-to-date, indicating pressure on margins.
• Cost of products sold increased significantly by $14.3 million in Q3 2025 and $27.5 million year-to-date, partly due to increased tariffs and higher net sales.
• Surgical pain and recovery net sales decreased by 7.9% in Q3 2025 and 8.9% year-to-date, mainly due to lower volume in the Game Ready product line.
• Cash and cash equivalents decreased by $37.2 million from December 31, 2024, reflecting increased cash usage for investing and financing activities.
• Restructuring costs related to the Post-RH Divestiture Plan increased to $10.3 million in Q3 2025 and $17.9 million year-to-date, indicating ongoing expenses associated with the transformation.

Risks

• General economic conditions, particularly in the United States, could adversely affect product demand.
• Pricing pressures, including cost-containment measures, could negatively impact product prices or demand.
• Fluctuations in global equity and fixed-income markets could affect financial performance.
• The company's ability to successfully execute or achieve the expected benefits of its restructuring initiatives is uncertain.
• Supply chain issues and inflationary pressures could increase costs and disrupt operations.
• A resurgence of the COVID-19 pandemic could adversely impact business operations.
• Changes in the competitive environment could affect market share and profitability.
• The loss of current customers or inability to obtain new customers could reduce revenue.
• Cybersecurity threats, including breaches or cyberattacks on information systems, pose operational and financial risks.
• Ongoing regional conflicts between Russia and Ukraine and in the Middle East could disrupt global markets and supply chains.
• Concentration of manufacturing operations in Mexico exposes the company to regional risks.
• Reductions in or eliminations of reimbursements from government healthcare programs or private health insurers could harm demand for products.
• Financial conditions affecting the banking system and potential threats to the solvency of commercial banks could impact liquidity.
• Litigation and enforcement actions could result in significant costs or operational restrictions.
• Disruption in the supply of raw materials or the distribution of finished goods could affect production and sales.
• Price fluctuations in key commodities could impact cost of goods sold.
• The imposition of new and increased U.S. tariffs and retaliatory trade measures by other countries could materially adversely affect business, financial condition, results of operations, and cash flows, particularly given reliance on manufacturing in Mexico and Canada, and sourcing from China and Mexico.
• Changes in, or revised interpretations of, import-export laws or international trade agreements (e.g., USMCA, WTO) could lead to additional tariffs or trade restrictions.
• Fluctuations in currency exchange rates could impact financial results.
• Changes in governmental regulations applicable to the business could increase compliance costs or restrict operations.
• The company's ability to realize the intended benefits of its restructuring initiatives or its divestiture, acquisition, or merger transactions is not assured.
• Changes in asset valuations, including write-downs of assets such as inventory, accounts receivable, or other assets for impairment or other reasons, could negatively impact financial statements.
• A proposed Medicare coverage policy change for RFA treatment for peripheral nerve pain, with a final determination expected in early 2026, could eliminate Medicare reimbursements for such treatments, materially affecting sales of RFA products.

Future Outlook

The company expects its Post-RH Divestiture Plan, as previously defined, to be substantially complete by the end of 2025. However, subsequent to Q3 2025, the plan was expanded following a new CEO's organizational assessment, with these expanded initiatives expected to run through 2026 and incur up to $10.0 million in incremental expenses, primarily for employee severance and benefits. These expanded initiatives are anticipated to yield annualized savings of $15.0 million to $20.0 million. The final valuations for the Nexus Medical acquisition are expected to be substantially complete by the end of 2025. A final determination on a proposed Medicare coverage policy for RFA treatment for peripheral nerve pain is expected in early 2026, which could impact RFA product sales. The company expects operating cash flow to be sufficient to meet working capital requirements and fund capital expenditures for the next twelve months and for the foreseeable future.

Management Comments

• We expect the acquisition of Nexus will enhance our Specialty Nutrition Systems (SNS) portfolio of products.
• We expect the Plan will be substantially complete by the end of 2025.
• Subsequent to the end of the third quarter of 2025, the assessment of our organization performed in conjunction with the recent appointment of our Chief Executive Officer was completed and the Plan was expanded to align our organizational structure with our business needs.
• We anticipate annualized savings from these initiatives to be between $15.0 million and $20.0 million.
• This transaction aligns with our ongoing transformation, which is focused on advancing our strategic segments, PM&R and SNS.
• We expect our operating cash flow will be sufficient to meet our working capital requirements and fund capital expenditures in the next twelve months.
• We do not expect restrictions on repatriation of cash held outside of the United States to have a material effect on our overall liquidity, financial condition or results of operations for the foreseeable future.
• At present, although the results of litigation and claims cannot be predicted with certainty, we believe that the ultimate resolution of any pending legal proceeding to which we are a party will not have a material adverse effect on our business, financial condition, results of operations or liquidity.

Industry Context

Avanos Medical operates in the medical technology sector, focusing on specialty nutrition and pain management. The acquisition of Nexus Medical strengthens its position in neonate solutions within the Specialty Nutrition Systems segment, aligning with a broader industry trend towards specialized, high-acuity care products. The divestiture of the HA product line and the ongoing restructuring reflect a strategic pivot towards higher-margin, higher-growth core segments, a common strategy for medical device companies optimizing their portfolios. The company faces industry-wide challenges such as pricing pressures, supply chain disruptions, and evolving healthcare reimbursement policies, particularly highlighted by the potential Medicare policy change for RFA treatments, which could significantly impact its Pain Management and Recovery segment.

Legal Proceedings

• The Deferred Prosecution Agreement (DPA) with the United States Department of Justice (DOJ) related to MicroCool surgical gowns was resolved, and the DOJ's case against the company was dismissed in January 2025.
• The company is subject to various legal proceedings, claims, and governmental inspections, audits, or investigations, but believes the ultimate resolution will not have a material adverse effect on its business, financial condition, results of operations, or liquidity.

Related Party Transactions

• The company is obligated to indemnify Kimberly-Clark Corporation for legal proceedings, claims, and other liabilities primarily related to its business prior to the 2014 spin-off. No costs were incurred for such indemnification matters in the nine months ended September 30, 2025 or 2024.

Stakeholder Impact

• Shareholders are negatively impacted by the significant net loss, operating loss, and goodwill impairment, which reduced total stockholders' equity. Future annualized savings from restructuring could be a long-term positive.
• Employees are impacted by ongoing restructuring initiatives, which include employee severance and benefits costs, particularly with the expanded plan through 2026.
• Customers in the Specialty Nutrition Systems segment may benefit from enhanced product offerings through the Nexus Medical acquisition.
• Customers utilizing RFA treatments for peripheral nerve pain face uncertainty due to a proposed Medicare coverage policy change, which could affect access and reimbursement.
• Suppliers may be affected by supply chain adjustments and cost containment measures implemented to mitigate tariff impacts.
• Creditors benefit from the reduction in long-term debt, but the overall financial performance and operating losses present a higher risk profile.

Next Steps

• Continue execution of the expanded Post-RH Divestiture Plan initiatives through 2026.
• Finalize valuations for the Nexus Medical acquisition by the end of 2025.
• Monitor and advocate regarding the final determination of the proposed Medicare coverage policy for RFA treatment for peripheral nerve pain, expected in early 2026.
• Continue to provide limited transition services related to the RH Divestiture, which will terminate no later than three years following October 2, 2023.

Key Dates

Recommendation

Avanos Medical's Q3 2025 filing reveals a challenging financial period, marked by a substantial net loss and operating loss for the nine months, primarily due to a $77.0 million goodwill impairment. While the company is actively pursuing strategic portfolio optimization through the Nexus acquisition and HA asset divestiture, and showing revenue growth in its core SNS and RFA segments, the significant losses and ongoing, expanded restructuring efforts introduce considerable uncertainty. The potential adverse change in Medicare reimbursement for RFA treatments also poses a material risk. Given the mixed signals of strategic progress against a backdrop of weak financial performance and operational restructuring, a 'hold' recommendation is appropriate. Investors should monitor the execution of restructuring plans, the realization of anticipated savings, and the outcome of the RFA reimbursement policy decision before making further investment decisions.

Keywords

Medical Technology, SEC Filing, 10-Q, Avanos Medical, AVNS, Financial Results, Goodwill Impairment, Restructuring, Acquisition, Nexus Medical, Specialty Nutrition Systems, Pain Management and Recovery, Radiofrequency Ablation, Enteral Feeding, Neonate Solutions, Tariffs, Healthcare Reimbursement, Medical Devices